Univar Solutions Inc. a leading global solutions provider to users of specialty ingredients and chemicals, today announced the Company has reached an agreement with W. R. Grace & Co. ("Grace") to distribute Grace's SYLOID® FP silica for pharmaceutical and nutraceutical markets in the majority of European countries*.
Blueprint Medicines Corporation announced that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (ISM). All U.S. patients with ISM now have access to the first and only approved medicine designed to treat their disease.
Abbott announced its Assert-IQ™ insertable cardiac monitor (ICM) has received U.S. Food and Drug Administration (FDA) clearance, giving physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing irregular heartbeats.
CardieX Limited announced its new arterial health monitor, the CONNEQT Pulse (Pulse), has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
Sai Life Sciences, one of India's fastest growing global Contract Research, Development & Manufacturing Organisations (CRO-CDMO), announced the opening of Sai Schrödinger Research Laboratories (SSRL).
Global private investment firm, Bridgewest Group, recognized for developing innovative companies in life sciences, software, and deep tech, announces that it has completed the acquisition of the Perth sterile injectable manufacturing facility from Pfizer (Perth) Pty Ltd, a subsidiary of Pfizer, Inc.
Sintetica S.A., an international pharmaceutical company with manufacturing facilities in Switzerland, announces the launch of Lidocaine Hydrochloride Injection, USP 1%, 2% and 4% through its subsidiary Sintetica US.
Anton Jorgensen, MD and Ortho San Antonio has announced the first cases in the BalancedBack Total Joint Replacement pivotal clinical trial using the breakthrough 3Spine MOTUS device, as an alternative to lumbar spinal fusion surgery. Dr. Jorgensen completed the surgeries at the Foundation Surgical Hospital of San Antonio.
Nexus Pharmaceuticals, Inc. has announced that it has received US Food and Drug Administration (FDA) approval for EMERPHED® (ephedrine sulfate injection) in 25mg/5mL and 50mg/10mL single-dose pre-filled syringes. The 10mL presentation is the first and only FDA-approved ready-to-administer 10mL pre-filled syringe available.
Fresenius Kabi had announced the immediate availability in the U.S. of Stimufend® (pegfilgrastim-fpgk), the company’s biosimilar to Neulasta® (pegfilgrastim), for use in patients at risk for febrile neutropenia, a common side effect of many anti-cancer medications. Stimufend is available in a single-dose, pre-filled syringe that delivers 6mg/0.6mL solution for subcutaneous injection.